About This Course

This is a podcast based course for oncologists, primary care physicians, gynecologists, nurse practitioners, and any other healthcare professionals treating patients suffering with breast cancer.

In this episode focused on breast cancer Dr Hope Rugo summarizes the TROPICS02 trial that she presented at this year's conference. We also discuss how data presented from the METEORA and ICON trials add to clinical understandings of immunotherapy response. Coverage is also provided to the ADAPT trial. Finally, we discuss how these clinical improvements in response and progression free survival (PFS) translate to the patient experience. 

After listening to the podcast, take the optional posttest and receive a certificate of completion. 

This course should take you approximately 40 minutes to complete.

This course has a 2-year expiry date of 15th May 2025. If you complete this course after its expiry date, please double check all claims in this course with up-to-date, peer-reviewed information, as the diagnostic or treatment landscape may have changed.

Learning Objectives

At the end of this course, students will be able to:

  • Describe the findings of the TROPICS02, METEORA, ICON and ADAPT trials.

  • Expand their clinical understandings of immunotherapy response.

  • Describe the risks and benefits of chosen therapy to support their patients.


Dr Hope S. Rugo, MD, FASCO, is professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, where she is also the director of Breast Oncology and Clinical Trials Education. Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at University of California San Francisco in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

Course curriculum

    1. Welcome to the Course

    1. Supplementary Material

    2. ESMO 2022 - Exploring the Latest Trial Data and Advances in Breast Cancer Treatments (Video)

    1. Introduction to Final Quiz

    2. Final Quiz

    1. Course Feedback Survey

About this course

  • Free
  • 6 lessons
  • 0.5 hours of video content

This podcast episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company.